论文部分内容阅读
目前,链球菌制剂 OK-432作为非特异性免疫活性剂,在日本已广泛用于临床。该药一般经肌肉注射或皮内注射全身性给药,但偶可用于瘤体内直接注射。作者采用皮内注射与内窥镜引导下瘤体内直接注射 OK-432,治疗11例不宜手术胃癌患者,对其临床效果进行了研究。病人男6例,女5例,平均年龄为78.7岁。因肝转移、严重并发症、年迈等原因不宜手术治疗。方法是将 OK-432 5～10mg 溶于2～5ml生理盐水,每次瘤体内及其附近组织注射0.5ml,每周1次;OK-432 5mg 隔天皮内注射作为全身给药,总量35～540 mg/4～54次。不
Currently, the streptococcal agent OK-432 is used as a non-specific immunoactive agent and has been widely used in clinical practice in Japan. The drug is generally administered intramuscularly or intradermally, but it can also be used for direct injection into the tumor. The authors used intradermal injection and endoscopic guided direct injection of OK-432 to treat 11 patients with unsuitable surgery for gastric cancer. Their clinical effects were studied. The patient had 6 males and 5 females with an average age of 78.7 years. Due to liver metastases, serious complications, and age, it is not suitable for surgical treatment. The method is to dissolve OK-432 5~10mg into 2~5ml normal saline, and inject 0.5ml each time in the tumor tissue and its nearby tissues once a week; OK-432 5mg is injected intradermally every other day as systemic administration. 35 to 540 mg/4 to 54 times. Do not